PTPN11 and neoplasm: Defining the functional and biochemical activity of immune checkpoints both in cancerous cells and in tumour microenvironment of TC will expand our knowledge allowing to develop rational therapeutic strategies for aggressive TC exploiting ICI in combination with SHP2 or RTK/Ras/MAPK inhibitors.